Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Latent viral infections of the nervous system: role of the host immune response.

Lafon M.

Rev Neurol (Paris). 2009 Dec;165(12):1039-44. doi: 10.1016/j.neurol.2009.09.010. Review.

2.
3.

Herpes simplex virus latent infection in the nervous system.

Steiner I, Kennedy PG.

J Neurovirol. 1995 Mar;1(1):19-29. Review.

PMID:
9222339
4.

Immune control of HSV-1 latency.

Decman V, Freeman ML, Kinchington PR, Hendricks RL.

Viral Immunol. 2005;18(3):466-73. Review.

PMID:
16212525
5.

Recognition of herpes simplex viruses: toll-like receptors and beyond.

Ma Y, He B.

J Mol Biol. 2014 Mar 20;426(6):1133-47. doi: 10.1016/j.jmb.2013.11.012. Epub 2013 Nov 19. Review.

6.

A triple entente: virus, neurons, and CD8+ T cells maintain HSV-1 latency.

Divito S, Cherpes TL, Hendricks RL.

Immunol Res. 2006;36(1-3):119-26. Review.

PMID:
17337772
7.

Immunological control of herpes simplex virus infections.

Egan KP, Wu S, Wigdahl B, Jennings SR.

J Neurovirol. 2013 Aug;19(4):328-45. doi: 10.1007/s13365-013-0189-3. Epub 2013 Aug 14. Review.

8.

Herpes simplex virus latency and the immune response.

Daheshia M, Feldman LT, Rouse BT.

Curr Opin Microbiol. 1998 Aug;1(4):430-5. Review.

PMID:
10066506
9.

Role of IFN-gamma and tumor necrosis factor-alpha in herpes simplex virus type 1 infection.

Minami M, Kita M, Yan XQ, Yamamoto T, Iida T, Sekikawa K, Iwakura Y, Imanishi J.

J Interferon Cytokine Res. 2002 Jun;22(6):671-6.

PMID:
12162877
10.

Defining nervous system susceptibility during acute and latent herpes simplex virus-1 infection.

Menendez CM, Carr DJJ.

J Neuroimmunol. 2017 Jul 15;308:43-49. doi: 10.1016/j.jneuroim.2017.02.020. Epub 2017 Mar 8. Review.

11.

Immunity in latent Herpes simplex virus infection.

Bystrická M, Russ G.

Acta Virol. 2005;49(3):159-67. Review.

PMID:
16178513
12.

Gamma interferon can prevent herpes simplex virus type 1 reactivation from latency in sensory neurons.

Liu T, Khanna KM, Carriere BN, Hendricks RL.

J Virol. 2001 Nov;75(22):11178-84.

13.

Immune control of herpes simplex virus during latency.

Khanna KM, Lepisto AJ, Decman V, Hendricks RL.

Curr Opin Immunol. 2004 Aug;16(4):463-9. Review.

PMID:
15245740
15.

The neurotropic herpes viruses: herpes simplex and varicella-zoster.

Steiner I, Kennedy PG, Pachner AR.

Lancet Neurol. 2007 Nov;6(11):1015-28. Review.

PMID:
17945155
16.
17.

Chromatin control of herpes simplex virus lytic and latent infection.

Knipe DM, Cliffe A.

Nat Rev Microbiol. 2008 Mar;6(3):211-21. doi: 10.1038/nrmicro1794. Review.

PMID:
18264117
18.

Reevaluating the CD8 T-cell response to herpes simplex virus type 1: involvement of CD8 T cells reactive to subdominant epitopes.

Sheridan BS, Cherpes TL, Urban J, Kalinski P, Hendricks RL.

J Virol. 2009 Mar;83(5):2237-45. doi: 10.1128/JVI.01699-08. Epub 2008 Dec 10.

19.

Acute morphine administration reduces cell-mediated immunity and induces reactivation of latent herpes simplex virus type 1 in BALB/c mice.

Mojadadi S, Jamali A, Khansarinejad B, Soleimanjahi H, Bamdad T.

Cell Mol Immunol. 2009 Apr;6(2):111-6. doi: 10.1038/cmi.2009.15.

20.

Glycoprotein G of herpes simplex virus 2 as a novel vaccine antigen for immunity to genital and neurological disease.

Görander S, Harandi AM, Lindqvist M, Bergström T, Liljeqvist JÅ.

J Virol. 2012 Jul;86(14):7544-53. doi: 10.1128/JVI.00186-12. Epub 2012 May 2.

Supplemental Content

Support Center